Search Within

Joseph Patrick Erinjeri

Formats
  1. Journal Article (131)
  2. Meeting Abstract (58)
  3. Book Section (5)
  4. Review (4)
  5. Research Letter (2)
  6. Correspondence (1)
  7. Editorial (1)
  8. Guidelines (1)
Groups
  1. Interventional Radiology Service (203)
  2. Radiology, Department of (203)
  3. Center for Pancreatic Cancer Research (126)
  4. Department of Medicine (88)
  5. Solid Tumor Oncology Division (84)
  6. Sloan Kettering Institute Postdocs (60)

More Groups

People
  1. Stephen Solomon (91)
  2. Constantinos Sofocleous (65)
  3. Hooman Yarmohammadi (60)
  4. Etay Ziv (47)
  5. Karen Brown (37)
  6. George Getrajdman (34)

More People

Years
  1. 2025 (7)
  2. 2024 (24)
  3. 2023 (21)
  4. 2022 (26)
  5. 2021 (5)
  6. 2020 (14)

More Years

Publications
  1. Journal of Vascular and Interventional Radiology (46)
  2. Journal of Clinical Oncology (28)
  3. CardioVascular and Interventional Radiology (15)
  4. Radiology (10)
  5. Annals of Oncology (6)
  6. Clinical Cancer Research (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (53)
  2. Springer (35)
  3. American Society of Clinical Oncology (31)
  4. Radiological Society of North America, Inc. (10)
  5. American Association for Cancer Research (6)
  6. Oxford University Press (6)

More Publishers

Results (203)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant plus abemaciclib in hormone receptor–positive advanced or recurrent endometrial cancer
    Journal Article

    Green, A. K.; Zhou, Q.; Iasonos, A.; Zammarrelli, W. A. 3rd; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Loh, J.; Hom, V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis
    Meeting Abstract

    Sangro, B.; Bouattour, M.; Park, J. W.; Diaz, C.; Erinjeri, J. P.; Alves, G. V.; Gu, S. Z.; Manikhas, A.; Kuroda, H.; Suksombooncharoen, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis
    Meeting Abstract

    Heo, J.; Okusaka, T.; Yoon, J. H.; Sangro, B.; Chan, S. L.; Erinjeri, J. P.; Matos, M.; Decaens, T.; Chen, E. X.; Beg, M. S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S. L.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases
    Journal Article

    Sotirchos, V. S.; Vakiani, E.; Sigel, C.; Imam, R.; Kunin, H. S.; Cooke, T. M.; Gönen, M.; Solomon, S. B.; Erinjeri, J. P.; Sofocleous, C. T.
    Cytotechnology (2025)

    Fulltext@MSK | Save
  • TP53 mutation predicts worse survival and earlier local progression in patients with hepatocellular carcinoma treated with transarterial embolization
    Journal Article

    Zhao, K.; Karimi, A.; Kelly, L.; Petre, E.; Marinelli, B.; Alexander, E. S.; Sotirchos, V. S.; Erinjeri, J. P.; Covey, A.; Sofocleous, C. T.; more...
    Current Oncology (2025)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Lencioni, R.; Erinjeri, J. P.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V.; Bouattour, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Kudo, M.; Lencioni, R.; Erinjeri, J.; Chan, S. L.; Qin, S.; Ren, Z.; Arai, Y.; Heo, J.; Breder, V. V.; Bouattour, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save